Rowan Courtney M, Gertz Shira J, Zinter Matt S, Moffet Jerelyn, Bajwa Rajinder P S, Barnum Jessie L, Kong Michele
Department of Pediatrics, Division of Critical Care, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Department of Pediatrics, St Barnabas Medical Center, Livingston, NJ, USA.
Transpl Infect Dis. 2018 Jun;20(3):e12882. doi: 10.1111/tid.12882. Epub 2018 Apr 2.
Hematopoietic cell transplant (HCT) may be a risk factor for morbidity and mortality from respiratory syncytial virus (RSV). Previous studies have been limited by small sample size. We took a multicenter approach with the goal of better understanding the epidemiology, risk factors, treatment, morbidity, and mortality associated with RSV infections among children with HCT in the United States.
A retrospective, multicenter, cohort study of pediatric HCT recipients were diagnosed with RSV infection between January 2010 and December 2014.
Of the 1522 HCT, 47 (3%) patients were diagnosed with RSV. Of those with RSV, 9 (19.1%) were admitted to the pediatric intensive care unit (PICU), 6 (12.8%) received invasive mechanical ventilation, and 1 died. Prophylactic palivizumab was uncommon. All who required critical care received ribavirin vs 7.3% of those who did not (P = .004). Cobacterial infections were found in 16 patients and were not associated with the need for critical care. We examined potential risk factors for severity of RSV disease. In those who received invasive ventilation, 100% had one of the preidentified risk factors. Half of those requiring mechanical ventilation were diagnosed with RSV during their conditioning for transplant as opposed to only 2.4% of those that did not require invasive mechanical ventilation (P = .005).
In this multicenter cohort, RSV was not common in children following HCT. Few children infected with RSV required critical care and mortality was low. Those diagnosed with RSV during conditioning for transplant were at higher risk for invasive mechanical ventilation.
造血细胞移植(HCT)可能是呼吸道合胞病毒(RSV)导致发病和死亡的一个风险因素。以往的研究受样本量小的限制。我们采用多中心研究方法,旨在更好地了解美国接受HCT的儿童中与RSV感染相关的流行病学、风险因素、治疗、发病率和死亡率。
对2010年1月至2014年12月期间被诊断为RSV感染的儿科HCT受者进行一项回顾性、多中心队列研究。
在1522例HCT中,47例(3%)患者被诊断为RSV感染。在这些RSV感染患者中,9例(19.1%)入住儿科重症监护病房(PICU),6例(12.8%)接受有创机械通气,1例死亡。预防性使用帕利珠单抗并不常见。所有需要重症监护的患者均接受了利巴韦林治疗,而未接受重症监护的患者中这一比例为7.3%(P = 0.004)。16例患者发现合并细菌感染,且与是否需要重症监护无关。我们研究了RSV疾病严重程度的潜在风险因素。在接受有创通气的患者中,100%有预先确定的风险因素之一。需要机械通气的患者中有一半在移植预处理期间被诊断为RSV感染,而不需要有创机械通气的患者中这一比例仅为2.4%(P = 0.005)。
在这个多中心队列中,RSV在HCT后的儿童中并不常见。很少有感染RSV的儿童需要重症监护,死亡率较低。在移植预处理期间被诊断为RSV感染的儿童接受有创机械通气的风险较高。